Literature DB >> 18389300

[Analgesic intolerance (AI). Key position of ENT physicians for early detection of this condition].

U Förster1, H Olze.   

Abstract

The clinical manifestation of analgesic intolerance (AI) is frequently associated with symptoms examined by ear-nose-throat (ENT) specialists. The prevalence of AI is reported in the literature to be 0.6-2.5%. Even though there are no concluding results concerning its pathogenesis, an altered arachidonic acid metabolism is most likely the underlying pathomechanism. The symptoms include chronic rhinosinusitis with nasal polyps, asthma, gastrointestinal ulcers, angioedema, and urticaria. Clinical reactions after ingestion of nonsteroidal anti-inflammatory-drugs (NSAIDs) are often obvious in the progress of disease. In order to initiate early therapy and therefore prevent the progress of disease, the diagnosis of AI should occur before the complete picture of AI is obvious. Adaptive desensitization is currently the single causal therapy. Frequency of endonasal revision surgery is reduced after desensitization; severe asthma and reactions after ingestion of NSAIDs are avoided. ENT specialists are particularly in a key position for early detection of AI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18389300     DOI: 10.1007/s00106-008-1701-6

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  24 in total

1.  [Application of the nasal provocation test on diseases of the upper airways. Position paper of the German Society for Allergology and Clinical Immunology (ENT Section) in cooperation with the Working Team for Clinical Immunology].

Authors:  H Riechelmann; C Bachert; O Goldschmidt; B Hauswald; L Klimek; W W Schlenter; A J Tasman; M Wagenmann
Journal:  Laryngorhinootologie       Date:  2003-03       Impact factor: 1.057

Review 2.  [Revised terminology for allergies and related conditions].

Authors:  R Gerth van Wijk; P B van Cauwenberge; S G O Johansson
Journal:  Ned Tijdschr Geneeskd       Date:  2002-11-30

3.  [Rhinosinusitis guidelines of the German Society for Otorhinolaryngology, Head and Neck Surgery].

Authors:  B A Stuck; C Bachert; P Federspil; W Hosemann; L Klimek; R Mösges; O Pfaar; C Rudack; H Sitter; M Wagenmann; K Hörmann
Journal:  HNO       Date:  2007-10       Impact factor: 1.284

4.  Concerning the nature of intolerance to aspirin.

Authors:  M Samter; R F Beers
Journal:  J Allergy       Date:  1967-11

5.  Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics.

Authors:  D Schäfer; M Schmid; U C Göde; H W Baenkler
Journal:  Eur Respir J       Date:  1999-03       Impact factor: 16.671

6.  [Treatment of ASS-Associated Polyposis (ASSAP) with a cysteinyl leukotriene receptor antagonist - a prospective drug study on its antiinflammatory effects].

Authors:  T Grundmann; M Töpfner
Journal:  Laryngorhinootologie       Date:  2001-10       Impact factor: 1.057

7.  Organizational principles in the peripheral sympathetic nervous system: subdivision by coexisting peptides (somatostatin-, avian pancreatic polypeptide-, and vasoactive intestinal polypeptide-like immunoreactive materials).

Authors:  J M Lundberg; T Hökfelt; A Anggård; L Terenius; R Elde; K Markey; M Goldstein; J Kimmel
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

Review 8.  Aspirin and NSAID sensitivity.

Authors:  Donald D Stevenson
Journal:  Immunol Allergy Clin North Am       Date:  2004-08       Impact factor: 3.479

Review 9.  Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management.

Authors:  Andrew Szczeklik; Donald D Stevenson
Journal:  J Allergy Clin Immunol       Date:  2003-05       Impact factor: 10.793

10.  Effect of inhaled prostaglandin E2 on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma.

Authors:  I D Pavord; A Wisniewski; R Mathur; I Wahedna; A J Knox; A E Tattersfield
Journal:  Thorax       Date:  1991-09       Impact factor: 9.139

View more
  1 in total

1.  [Aspirin desensitization: therapy options in patients with aspirin-exacerbated respiratory disease].

Authors:  R Weber; A Trautmann; W Randerath; W Heppt; W Hosemann
Journal:  HNO       Date:  2012-04       Impact factor: 1.284

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.